z-logo
Premium
The alpha‐adrenoceptor subtype mediating the tension of human prostatic smooth muscle
Author(s) -
Lepor Herbert,
Tang Rui,
Shapiro And Ellen
Publication year - 1993
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990220404
Subject(s) - phenylephrine , receptor , prostate , endocrinology , medicine , hyperplasia , contraction (grammar) , agonist , muscle contraction , biology , cancer , blood pressure
We have characterized the α 1 adrenoceptor subtypes in the human prostate using radioligand receptor binding studies. The objective of the present study was to determine the α 1 subtype mediating the tension of prostatic smooth muscle. Fresh human tissue was obtained from 9 males between 50 and 80 years of age undergoing prostatectomy for BPH. The incubation of prostatic tissue with the irreversible antagonist chlorethyclonidine (CEC) resulted in an 80% reduction of the maximal contractile response produced by phenylephrine. However, the α 1A ‐selective antagonists WB‐4101 and 5‐methylurapidil (5‐MU) competitively inhibited the contractile response induced by phenylephrine, with K B = 2.64 and 4.46 nM, respectively, consistent with their affinity at the α A1 receptor subtype. The pharmacological profile of the α 1 ‐receptor‐mediated contractile response of prostate smooth muscle is inconsistent with their classification as either an α 1A or α 1B subtype. Alternatively, when compared with the properties of the cloned α 1 receptors, our results suggest that the α 1 receptors involved in the contraction of prostate smooth muscle have some pharmacological properties similar to those encoded by the gene of the bovine α 1c receptor subtype. The findings of the present study suggest that efforts should be made to confirm the identity of the α 1 ‐receptor subtype expressed by prostate smooth muscle, in order to develop subtype‐selective α 1 antagonists, and to evaluate their safety and efficacy in benign prostatic hyperplasia (BPH). © 1993 Wiiey‐Liss, inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom